Vaxcyte to Present at the Jefferies Healthcare Conference
02 juin 2022 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
09 mai 2022 16h10 HE
|
Vaxcyte, Inc.
-- Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease...
Vaxcyte to Participate in Upcoming Investor Conferences in May
03 mai 2022 08h30 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
05 avr. 2022 08h30 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
04 avr. 2022 08h30 HE
|
Vaxcyte, Inc.
-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned -- -- Company Expects to Announce Topline Results...
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
28 févr. 2022 16h10 HE
|
Vaxcyte, Inc.
-- First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults -- -- VAX-24 Phase 1/2 Study Topline Safety,...
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
23 févr. 2022 16h05 HE
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 -- --...
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
17 févr. 2022 08h30 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 08h30 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
Vaxcyte Announces Pricing of $100 Million Public Offering
13 janv. 2022 01h07 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...